The axiom that diagnosis must precede treatment holds true for the management of short stature. What matters is the current rate of growth and the potential for further growth; it is essential to measure accurately the rate of gain in height and the radiological bone age. Early detection of subnormal rate of growth can lead to prevention of dwarfism, but a dwarf with epiphyses closed is beyond remedy.
A child's rate of gain in height is determined by genetic factors that require a benign internal environment for their full expression. No form of therapy can alter a genetically determined height velocity; treatment is possible if an adverse internal environment can be corrected. Smith' gave an excellent account of the various forms of dwarfism, including the many eponymous genetic syndromes. The genetic short stature of atypical Turner's syndrome may not be recognized unless the karyotype is known from chromosomal studies. A more common difficulty in diagnosis is the normal slow-growing short child of short parents; the normality is obvious only if the child's height is corrected for parental height, using the data of Tanner  et al.2 Any prolonged illness creates an adverse environment that slows the rate of gain of height. In the same way cyanotic congenital heart disease, chronic hepatic or renal failure, and uncontrolled diabetes mellitus stunt growth. Deficient food intake or absorption are more easily rectified causes of subnormal rate of gain of height. The dietary intake, both in quantity and quality, must be discovered. Steatorrhoea syndrome in children and from the many examples of systemic steroid therapy for non-endocrine disease. It is not so widely appreciated that the amount of glucocorticoid required to stunt growth is only a little above normal requirements. Therefore, it is of the utmost importance to keep steroid dosage to the minimum or to consider the use of minimal quantities of corticotrophin.
The role of anabolic steroids in growth in stature is confined to the puberty growth spurt. Failure to mature sexually and to grow as fast as their contemporaries is a common complaint among boys who have achieved normal childhood growth. The success of anabolic steroid or androgen therapy in these cases is not an argument for their use in childhood. At all times the rate of bone maturation exceeds that of the increased height velocity so that it is doubtful if anabolic steroids ever increase the height to a level above that which would eventually be-reached without therapy. The use of such steroids should be confined to inducing a puberty growth spurt.
In terms of physiology, diagnosis, and treatment the influence of pituitary growth hormone is of paramount importance and requires full consideration in any discussion of subnormal height velocity and its correction.
Diagnosis of Growth Hormone Deficiency
For much of the time the normal plasma levels of immunoassayable growth hormone are as low as they are in hypopituitarism and the normal transient peaks are as high as the persistent levels of active acromegaly. Consequently growth hormone deficiency can be detected only when little or no growth hormone can be found in the plasma under conditions that provoke maximal growth hormone secretion in the normal person. Many of these conditions (see Table I ) have been standardized in formal provocative tests, but in children fear is a dominant stimulus and planned provocation may produce no higher level of plasma growth hormone. Twenty-eight such patients in the M.R.C. trial achieved a mean height velocity of 9-1 cm for the first full year of treatment, compared with 31 cm for the pretreatment year. Those with the lowest height velocities before therapy showed the greatest acceleration when given growth hormone. The bone age velocity was 0-86 before therapy and 1 18 during the year of treatment.
The major point is that the acceleration in height velocity is greater than the acceleration in bone age velocity, thus reversing the situation found in isolated growth hormone deficiency. Tissue changes are also remedied. The administration of HGH reduces the amount of subcutaneous fat,'3 increases bone width, mainly of cortical bone,'2 and increases muscle bulk by cell multiplication rather than by increase in cell size.'7 There is, indeed, the clearest evidence that the defects in growth attributed to lack of growth hormone are corrected by administration of that hormone. A similar response to HGH nas been found in children with panhypopituitarism, but all reports indicate that the degree of response is less than that of patients with isolated growth hormone deficiency.
There is no good recorded evidence of HGH therapy being of real benefit to any child with short stature not due to deficiency of growth hormone. Of the 100 patients in the M.R.C. Trial, only those with growth hormone deficiency shown by immunoassay of plasma growth hormone during provocative tests showed a therapeutic response to long-term HGH administration. The short stature of Turner's syndrome is not affected appreciably by growth hormone, nor is the height velocity of the normal small child, or the dwarf of low birth weight. Growth hormone will not accelerate the low height velocity of children undergoing continuous steroid therapy.
INDICATIONS FOR TREATMENT
The evidence to date strongly suggests that growth hormone therapy should be used only in proved cases of growth hormone BRITISH MEDICAL JOURNAL 27 MAY 1972 deficiency. Within this context the most effective use of growth hormone may be discussed. For research purposes all patients in the M.R.C. trial had a year without treatment after a full year of HGH injections. Those who had shown a therapeutic response to a year's treatment showed a drop in height velocity in the subsequent year to below pretreatment levels; subsequent therapy failed fully to compensate for this. Therefore, once shown to be successful, treatment must be continuous over years. Moreover, being a substitution therapy, HGH injections should be started as early as possible to prevent actual dwarfism.
The very young do not respond any better than older children, but their disability may be prevented rather than alleviated. This is made clear by Figure 1 and 2 , which contrast the effects of late and early treatment on height. It must be remembered that the accelerated rate of gain in height gradually diminishes as treatment proceeds. Henneman The duration of effective treatment depends on the bone age and not the chronological age of the patient: 20-year-olds have a satisfying response to HGH provided their bone age is grossly retarded. Though data are insufficient for a dogmatic statement, it appears that a bone age of around 14 years heralds the beginning of the end of effective response to HGH.
Growth hormone itself increases the rate of gain in bone age, and every year of therapy brings the bone age at least one year nearer the critical point of no response. Anything that advances bone age more rapidly than height age will seriously diminish the effective duration of HGH therapy. Oestrogens, androgens, and anabolic steroids have such an effect and should never be given to a patient who is likely to require treatment with growth hormone or given during actual treatment with HGH until the patient has approached a height that could not be considered dwarfed in adult life. Of course, the spontaneous onset of puberty indicates that HGH therapy will soon lose its effect as bone age rapidly advances. Patients in whom puberty is delayed must face the fact that they cannot have early sexual maturity and normal height. They and their physicians have to weigh the disability of shortness against that of sexual immaturity.
The time taken for successful HGH treatment, started early to prevent dwarfism, makes heavy demands on the patient and on supplies of human growth hormone; twice-weekly injections have to be given until the child is at least 14 years old if the treatment is to be an effective substitution therapy. World experience suggests that a weekly dose of between 10 and 20 IU HGH gives a very satisfactory response in growth-hormonedeficient children. Doses of up to 40 IU weekly do not appear to produce a significantly better response than 10 IU. On a cost/benefit basis, 10 IU weekly is likely to be the optimum dose.
Role of Growth Hormone in Statural Growth
The hour-to-hour fluctuations of plasma growth hormone levels in response to and control of short-term metabolic adjustments are well-known. Raben20 suggested that growth hormone was an anticatabolic agent. This certainly fits its role in the short term and might well explain its long-term effect on statural growth, preventing influences that might diminish a genetically determined height velocity.
The effects of growth hormone on stature indicate that its action is dependent on other factors that it cannot over-ride.
It is only an effective stimulus to height velocity when that 90 is low due to growth hormone deficiency. Even under these con-50 ditions the effectiveness of growth hormone in maintaining a 10 normal height velocity is dependent on a benign environment. The story of respiratory stimulants has been repeatedly one of initial enthusiasm followed by gradual disillusionment. This is partly because they have been widely advocated for conditions in which they are not helpful and may be dangerous: neonatal asphyxia,' postanaesthetic apnoea, and drug overdosage.2 And yet an effective respiratory stimulant is needed, particularly for some patients with acute respiratory failure when the alternative may be mechanical ventilation, which, in these patients, carries an appreciable mortality. The indications in patients with chronic respiratory failure are much less clear. For patients who are hypercapnic, drowsy, and unable to cough adequately a respiratory stimulant is essentially "buying time"-the time necessary to allow other treatment, such as antibiotics, to be fully effective. The greatest need is to keep the patient awake and alert and thus able to cough effectively and remove bronchial secretions.
CHRONIC RESPIRATORY FAILURE
Though patients may occasionally benefit, the rationale behind giving long-term respiratory stimulants to patients with chronic respiratory failure is very much open to question. A respiratory stimulant will increase both minute ventilation and the work of breathing, which causes an increase in oxygen consumption and carbon dioxide (CO2) production by the respiratory muscles. Arterial Pco2 depends on the balance between co2 production and alveolar ventilation, and as both will be increased by respiratory stimulants there may be little change in arterial Pco2 despite an increase in ventilation.
Contraindications
Respiratory stimulants should not be given to certain patients. Firstly, in conditions where hypoxaemia is not associated with hypercapnia-for example, asthma. If the arterial PCO2 is normal or low then ventilatory drive is adequate and respiratory stimulants will do no good and may be harmful. Secondly, patients with respiratory failure due to neurological or muscular disease; and, finally, great caution should be taken in patients with epilepsy or coronary artery disease.
